ES2176342T3 - Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico. - Google Patents

Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico.

Info

Publication number
ES2176342T3
ES2176342T3 ES95936537T ES95936537T ES2176342T3 ES 2176342 T3 ES2176342 T3 ES 2176342T3 ES 95936537 T ES95936537 T ES 95936537T ES 95936537 T ES95936537 T ES 95936537T ES 2176342 T3 ES2176342 T3 ES 2176342T3
Authority
ES
Spain
Prior art keywords
type
sequences
hcv
new
subtipos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95936537T
Other languages
English (en)
Other versions
ES2176342T5 (es
Inventor
Geert Maertens
Lieven Stuyver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2176342(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of ES2176342T3 publication Critical patent/ES2176342T3/es
Application granted granted Critical
Publication of ES2176342T5 publication Critical patent/ES2176342T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS SECUENCIAS DE NUCLEOTIDOS GENOMICOS Y A LAS SECUENCIAS DE AMINOACIDOS CORRESPONDIENTES A LA REGION DE CODIFICACION DE ESTOS GENOMAS. LA INVENCION SE REFIERE A NUEVAS SECUENCIAS DE TIPOS Y SUBTIPOS DE HCV QUE SON DIFERENTES DE LAS SECUENCIAS DE TIPOS Y SUBTIPOS DE HCV CONOCIDAS. EN PARTICULAR, LA PRESENTE INVENCION SE REFIERE A NUEVAS SECUENCIAS DEL HCV TIPO 7, NUEVAS SECUENCIAS DEL HCV TIPO 9, NUEVAS SECUENCIAS DEL HCV TIPO 10 Y NUEVAS SECUENCIAS DEL HCV TIPO 11. LA PRESENTE INVENCION TAMBIEN SE REFIERE A NUEVAS SECUENCIAS DE LOS SUBTIPOS 1D, 1E, 1F Y 1G DEL HCV TIPO 1; NUEVAS SECUENCIAS DE LOS SUBTIPOS 2E, 2F, 2G, 2H, 2I, 2K Y 2L DEL HCV TIPO 2; NUEVAS SECUENCIAS DEL SUBTIPO 3G DEL HCV TIPO 3; NUEVAS SECUENCIAS DE LOS SUBTIPOS 4K, 4L Y 4M DEL HCV TIPO 4; A UN PROCESO PARA LA PREPARACION DE LAS MISMAS Y A SU USO PARA DIAGNOSTICOS, PROFILAXIS Y TERAPIAS. EN PARTICULAR, EN LA PRESENTE INVENCION SE PRESENTAN NUEVAS SECUENCIAS ESPECIFICAS PARA LOS TIPOSDE LAS REGIONES DEL NUCLEO, LAS REGIONES E1 Y LA NS5 DE NUEVOS HCV TIPO 7, 9, 10 Y 11, ASI COMO NUEVAS VARIANTES (SUBTIPOS) DE LOS HCV TIPO 1, 2, 3 Y 4. ESTAS SECUENCIAS NUEVAS DE HCV SON UTILES PARA DIAGNOSTICAR LA PRESENCIA GENOTIPOS O SEROTIPOS DEL HCV TIPO 1 Y/O TIPO 2 Y/O TIPO 3 Y/O TIPO 4 Y/O TIPO 7 Y/O TIPO 9 Y/O TIPO 10 Y/O TIPO 11 EN UNA MUESTRA BIOLOGICA. ADEMAS, LA DISPONIBILIDAD DE ESTAS NUEVAS SECUENCIAS ESPECIFICAS PARA LOS TIPOS PUEDE AUMENTAR LA SENSIBILIDAD GENERAL DE DETECCION DEL HCV Y DEBERIA DEMOSTRAR TAMBIEN SU UTILIDAD PARA FINES PROFILACTICOS Y TERAPEUTICOS.
ES95936537T 1994-10-21 1995-10-23 Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos. Expired - Lifetime ES2176342T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP94870166 1994-10-21
EP95870076 1995-06-28
EP95870076 1995-06-28

Publications (2)

Publication Number Publication Date
ES2176342T3 true ES2176342T3 (es) 2002-12-01
ES2176342T5 ES2176342T5 (es) 2010-02-09

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95936537T Expired - Lifetime ES2176342T5 (es) 1994-10-21 1995-10-23 Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos.

Country Status (12)

Country Link
US (2) US7129337B1 (es)
EP (2) EP0804584B2 (es)
JP (2) JPH10507643A (es)
AT (1) ATE218617T1 (es)
AU (1) AU702436B2 (es)
BR (1) BR9509421A (es)
CA (1) CA2201703A1 (es)
DE (1) DE69526973T3 (es)
DK (1) DK0804584T3 (es)
ES (1) ES2176342T5 (es)
PT (1) PT804584E (es)
WO (1) WO1996013590A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
CZ298268B6 (cs) 1998-04-17 2007-08-08 Innogenetics N. V. Imunodiagnostický test používající redukující cinidla
DE19980730D2 (de) * 1998-04-28 2001-05-10 Wolfgang Bergter Radioimmunpharmaka zur Therapie der Hepatitis C
EP1090033B2 (en) * 1998-06-24 2007-12-19 Innogenetics N.V. Particles of hcv envelope proteins: use for vaccination
AU2001292151B2 (en) * 2000-08-17 2006-05-04 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
ES2596753T3 (es) * 2003-08-29 2017-01-11 Fujirebio Europe N.V. Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
JP5138230B2 (ja) 2004-01-07 2013-02-06 サード・ウェーブ・テクノロジーズ・インク Ｃ型肝炎ウイルスの遺伝子型の決定方法
RU2267496C2 (ru) * 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
WO2007031867A2 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-stru tural ns3/4a fusion gene
US7919242B2 (en) 2005-06-30 2011-04-05 Roche Molecular Systems, Inc. Light emission modifiers and their uses in nucleic acid detection, amplification and analysis
MX2008007477A (es) 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
PT2046833E (pt) 2006-07-14 2013-11-27 Genentech Inc Anticorpo humanizado contra amilóide beta
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
EP2463390A1 (en) 2006-10-20 2012-06-13 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS5B genomic region
WO2008046923A2 (en) 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
BRPI0719379A2 (pt) 2006-11-24 2014-02-11 Ac Immune Sa Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
DK2170389T3 (en) 2007-06-12 2015-01-19 Ac Immune Sa Humanized antibodies against amyloid beta
EP2527366B1 (en) 2007-06-12 2017-08-16 AC Immune S.A. Monoclonal anti beta amyloid antibody
WO2009022939A1 (en) * 2007-08-09 2009-02-19 Uchrezhdenie Rossiiskoi Akademii Nauk Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Ran (Imb Ran) Method for identifying the genotype and subtype of hepatitis c virus on a biological microchip
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
EP2650308A3 (en) 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
AU2011239966B2 (en) 2010-04-16 2014-05-08 Ac Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
PE20140218A1 (es) 2010-10-07 2014-03-01 Ac Inmune S A Composicion farmaceutica
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
DK2890402T3 (da) 2012-08-31 2019-07-15 Sutro Biopharma Inc Modificerede aminosyrer omfattende en azidogruppe
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
RU2667429C2 (ru) * 2013-05-10 2018-09-19 Соединенные Штаты Америки, В Лице Секретаря, Департамента Здравоохранения И Социального Обеспечения Сша Композиции и способы для одновременного обнаружения hcv антигена/антитела
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
PT3041864T (pt) 2013-09-05 2021-10-26 Ab2 Bio Sa Proteína de ligação a il-18 (il-18bp) em doenças inflamatórias
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
UA128752C2 (uk) 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021224432A1 (en) 2020-05-06 2021-11-11 Ab2 Bio Sa Il-18 binding protein (il-18bp) in respiratory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CA3244428A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa IL-18 BINDING PROTEIN (IL-18BP) IN THE TREATMENT OF VEXAS SYNDROME
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225068B1 (en) † 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
JP3156200B2 (ja) 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のｈｃｖ分離株
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
CA2032381C (en) 1989-12-18 2006-02-21 Peter E. Highfield Viral agent
NZ238681A (en) 1990-06-25 1992-03-26 Univ Osaka Res Found Non-a, non-b hepatitis virus particles and their production
HU227548B1 (en) 1991-05-08 2011-08-29 Novartis Vaccines & Diagnostic Process for production of non-naturally occuring non-hcv-1 nucleic acids, forming a hybridization product, and detecting hcv genotypes
KR0185426B1 (ko) * 1991-06-24 1999-04-01 로버트 피. 블랙버언 씨형 간염 바이러스 폴리펩티드
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
DE69232859T2 (de) * 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
ES2065863T3 (es) 1991-11-21 2003-09-01 Common Services Agency Analisis para la deteccion de virus de la hepatitis c.
ATE551423T1 (de) * 1993-04-27 2012-04-15 Innogenetics Nv Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
CA2201703A1 (en) 1996-05-09
WO1996013590A3 (en) 1996-08-15
WO1996013590A2 (en) 1996-05-09
AU702436B2 (en) 1999-02-18
US6974864B2 (en) 2005-12-13
EP0804584B1 (en) 2002-06-05
US20020183508A1 (en) 2002-12-05
EP1076092A2 (en) 2001-02-14
JP2005118044A (ja) 2005-05-12
JPH10507643A (ja) 1998-07-28
DE69526973T3 (de) 2010-01-07
BR9509421A (pt) 1997-09-30
ES2176342T5 (es) 2010-02-09
AU3844095A (en) 1996-05-23
DE69526973D1 (de) 2002-07-11
EP0804584B2 (en) 2008-07-09
DK0804584T3 (da) 2002-09-23
ATE218617T1 (de) 2002-06-15
DE69526973T2 (de) 2003-01-02
EP0804584A1 (en) 1997-11-05
US7129337B1 (en) 2006-10-31
EP1076092A3 (en) 2001-03-28
PT804584E (pt) 2002-11-29

Similar Documents

Publication Publication Date Title
WO1996013590A3 (en) New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
DE69330372T2 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
Kanto et al. Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density‐gradient centrifugation related to degree of liver inflammation
Xu et al. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon)
Kolykhalov et al. Identification of a highly conserved sequence element at the 3'terminus of hepatitis C virus genome RNA
Widell et al. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications
BR9405334A (pt) Novas sequências de genótipos de vírus da hepatite c e seu uso como agentes terapêuticos e diagnóstico
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
MC2188A1 (fr) Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
DE69126617T2 (de) Nanbv diagnostik: für die untersuchung auf hepatitis c verwendbare polynukleotide
WO1999029871A3 (fr) Sequences de circovirus associe a la maladie de l'amaigrissement du porcelet (map)
CN108330210B (zh) 寨卡病毒、登革热病毒和基孔肯雅病毒核酸检测试剂盒及其用途
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
WO2003020970A3 (en) New hepatitis c virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
WO2000058524A3 (en) Typing of human enteroviruses
Han et al. Identification of the protease domain in NS3 of hepatitis C virus
Widjojoatmodjo et al. Comparative sequence analysis of classical swine fever virus isolates from the epizootic in The Netherlands in 1997–1998
Vilček et al. Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates
Fricke et al. A family of closely related bovine viral diarrhea virus recombinants identified in an animal suffering from mucosal disease: new insights into the development of a lethal disease in cattle
Haas et al. Analysis of the H gene, the central untranslated region and the proximal coding part of the F gene of wild-type and vaccine canine distemper viruses
Litov et al. Evaluation of the population heterogeneity of TBEV laboratory variants using high-throughput sequencing
Giangaspero et al. Genetic variety of bovine viral diarrhea virus 2 strains isolated from sheep
Ballinger-Crabtree et al. Partial nucleotide sequence of South American yellow fever virus strain 1899/81: structural proteins and NS1
PE20001331A1 (es) Identificacion de genotipos senv
Chowdhury et al. Detection of classical swine fever virus by RT-PCR in West Bengal, India